[人新生儿和婴儿中的血管活性肠肽。通过放射免疫测定法和放射受体测定法测量（作者译）]
[Vip in human neonates and infants. As measured by radioimmunoassay and radioreceptorassay (author's transl)].
作者信息
Dupont C, Besson J, Laburthe M, Bataille D, Rosselin G
出版信息
Ann Endocrinol (Paris). 1977 Mar-Apr;38(2):151-2.
The Vasoactive Intestinal Peptide (VIP) was assayed in the gut of human neonates and premature infants immediately after death or surgery. In these conditions, values ranged between 150 and 740 ng/g of bioled tissue. The implication of VIP in Vermer-Morrison syndrome is further assessed by the correlation between clinical symptomatology and plasma VIP levels. The immunoassayable VIP (IA-VIP) extracted from normal gut or tumor is shown to fully interact with specific receptor for VIP in liver. This fact suggests the biological potency of IA-VIP.
在人类新生儿和早产儿死亡或手术后立即对其肠道中的血管活性肠肽（VIP）进行了测定。在这些情况下，每克生物组织中的含量在150至740纳克之间。通过临床症状与血浆VIP水平之间的相关性，进一步评估了VIP在韦默-莫里森综合征中的意义。从正常肠道或肿瘤中提取的可免疫测定的VIP（IA-VIP）显示与肝脏中VIP的特异性受体完全相互作用。这一事实表明了IA-VIP的生物学活性。
Zotero 插件